Clinical Trial: Oral CBD Dosing Doesn’t Consistently Mitigate Experimental Pain in Healthy Volunteers

New York, NY: The administration of oral CBD is not consistently associated with analgesia in healthy volunteers exposed to experimentally-induced pain, according to clinical data published in the British Journal of Clinical Pharmacology

Researchers affiliated with Columbia University assessed the administration of various doses of purified CBD (200, 400, or 800mg) versus placebo in subjects exposed to experimental pain conditions. 

Investigators reported that CBD “failed to consistently affect pain threshold and tolerance … relative to placebo.” In some cases, CBD dosing was associated with increases in subjects’ perceptions of pain. 

Authors concluded: “CBD did not elicit consistent dose-dependent analgesia and in fact increased pain on some measures. Future studies exploring CBD-induced pain relief should consider using a more extensive pain assessment paradigm in different participant populations.”

Other studies have documented the anti-inflammatory effects of CBD, which may be useful in the treatment of chronic pain in certain pain populations. Moreover, the inhalation of whole-plant cannabis is well-established as an analgesic agent in various populations, particularly those suffering from neuropathy. 

Full text of the study, “The dose-dependent analgesic effects, abuse liability, safety and tolerability of oral cannabidiol in healthy humans,” appears in the British Journal of Clinical Pharmacology. Additional information on cannabis and chronic pain is available from NORML.